| abstract |
The present disclosure includes at least one composition comprising, for example, a therapeutic and / or reporter transgene, in particular a group B virus, such as a serotype 11 adenovirus, or a fiber, pentone and hexonated chimeric virus of Ad11, for example a pharmaceutical formulation comprising the virus. The present invention relates to a modified adenovirus provided with transgene, in particular the use of virus and virus formulations in treatment, more particularly in the treatment of cancer. The disclosure also encompasses virus preparation processes. |